Schonfeld Strategic Advisors LLC Inozyme Pharma, Inc. Transaction History

Schonfeld Strategic Advisors LLC

  • $13.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$4.14 - $7.66 $140,346 - $259,674
-33,900 Reduced 31.19%
74,800 $572,000
Q4 2023

Feb 14, 2024
SELL
$2.71 - $4.5 $550,617 - $914,310
-203,180 Reduced 65.15%
108,700 $463,000
Q3 2023

Nov 14, 2023
BUY
$4.09 - $7.0 $990,107 - $1.69 Million
242,080 Added 346.82%
311,880 $1.31 Million
Q2 2023

Aug 14, 2023
BUY
$4.93 - $6.74 $203,116 - $277,688
41,200 Added 144.06%
69,800 $388,000
Q1 2023

May 15, 2023
BUY
$1.3 - $5.73 $37,180 - $163,878
28,600 New
28,600 $163,000

Others Institutions Holding INZY

# of Institutions
90
Shares Held
53M
Call Options Held
3.7K
Put Options Held
5.8K
View Full List

About Inozyme Pharma, Inc.

INZY Quotes by TradingView
  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $118M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email